Optimal duration of treatment in surgical patients with calf venous thrombosis involving one or more veins

被引:37
作者
Ferrara, Filippo
Meli, Francesco
Amato, Corrado
Cospite, Valentina
Raimondi, Francesco
Novo, Giuseppe
Novo, Salvatore
机构
[1] Univ Palermo, Univ Med Hosp, Dept Angiol, I-90133 Palermo, Italy
[2] Univ Palermo, Univ Med Hosp, Dept Cardiol, I-90133 Palermo, Italy
关键词
D O I
10.1177/0003319706290745
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The aim of this study was to evaluate different durations of treatment in patients with calf venous thrombosis (CVT) involving 1 or more deep veins. The authors studied 2 groups of patients with postsurgical CVT diagnosed by echo-color Doppler. The first group consisted of 68 patients with CVT involving a single vein, and the second group consisted of 124 patients with CVF involving 2 or more veins. Immediately after diagnosis, all patients were treated with nadroparin calcium and sodium warfarin. Heparin treatment was withdrawn after 5-6 days of treatment, when the international normalized ratio (INR) was stabilized between 2 and 3. Each group was divided into 2 subgroups receiving anticoagulation treatment for 6 or 12 weeks, respectively. The endpoint was proximal extension of the thrombotic lesion, defined as the extension of the thrombus to the popliteal and/or femoral vein. In patients with single-vessel CVF there was no significant difference between the 2 subgroups, whereas in patients with CVT involving 2 or more vessels, a statistically significant difference was observed, the number of cases showing proximal extension of the thrombus being higher among patients treated for 6 weeks. Twelve weeks of anticoagulation treatment is better than 6 weeks only in patients with postsurgical CVT involving 2 or more veins.
引用
收藏
页码:418 / 423
页数:6
相关论文
共 33 条
[1]   Low recurrence rate after deep calf-vein thrombosis with 6 weeks of oral anticoagulation [J].
Astermark, J ;
Björgell, O ;
Lindén, E ;
Lethagen, S ;
Nilsson, P ;
Berntorp, E .
JOURNAL OF INTERNAL MEDICINE, 1998, 244 (01) :79-82
[2]   NADROPARIN CALCIUM - A REVIEW OF ITS PHARMACOLOGY AND CLINICAL-APPLICATIONS IN THE PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISORDERS [J].
BARRADELL, LB ;
BUCKLEY, MM .
DRUGS, 1992, 44 (05) :858-888
[3]  
Baumgartner I, 1998, INT ANGIOL, V17, P43
[4]  
Bosson JL, 1998, INT ANGIOL, V17, P260
[5]  
Breddin HK, 1999, SEMIN THROMB HEMOST, V25, P83
[6]   Nadroparin calcium - A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders [J].
Davis, R ;
Faulds, D .
DRUGS & AGING, 1997, 10 (04) :299-322
[7]  
de Groot MR, 2000, THROMB HAEMOSTASIS, V83, P412
[8]  
DIQUELOU A, 1995, THROMB HAEMOSTASIS, V74, P1286
[9]   Efficacy and safety of weight-adapted nadroparin calcium vs. heparin sodium in prevention of clinically evident thromboembolic complications in 1,190 general surgical patients [J].
Egger, B ;
Schmid, SW ;
Naef, M ;
Wildi, S ;
Büchler, MW .
DIGESTIVE SURGERY, 2000, 17 (06) :602-609
[10]  
Favretto Giuseppe, 2002, Ital Heart J Suppl, V3, P95